Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem Biol Lett. 2023;10(1):451.

Google Scholar 

Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–606.

Article  PubMed  PubMed Central  Google Scholar 

Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Mendez-Sanchez N, Yuen MF, Hwang JP. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;38:262–79.

Article  PubMed  Google Scholar 

Asafo-Agyei KO SH, Hepatocellular carcinoma, StatPearls. 2023.

Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

Article  PubMed  Google Scholar 

Hsu CC, Lee HC, Wei YH. Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World J Gastroenterol. 2013;19(47):8880–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Infantino V, Dituri F, Convertini P, Santarsiero A, Palmieri F, Todisco S, Mancarella S, Giannelli G, Iacobazzi V. (2019) Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim et Biophys Acta (BBA): Mol Basis Dis. 1865;1:38–47.

Google Scholar 

Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene. 2006;25(34):4647–62.

Article  CAS  PubMed  Google Scholar 

Lee HC, Wei YH. Mitochondrial DNA instability and metabolic shift in human cancers. Int J Mol Sci. 2009;10(2):674–701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lozano-Rosas MG, Chávez E, Aparicio-Cadena AR, Velasco-Loyden G, Sánchez VCD. Mitoepigenetics and hepatocellular carcinoma. Hepatoma Res. 2018;4:19.

Article  Google Scholar 

Liu Y, Chen C, Wang X, Sun Y, Zhang J, Chen J, Shi Y. An epigenetic role of mitochondria in cancer. Cells. 2022;11(16):2518.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asma MA, Hussien AE. Natural products and hepatocellular carcinoma: a review. Hepatoma Res. 2015;1:119–24.

Article  Google Scholar 

Li Y, Li H, He Q, Yang X. Potential of compounds originating from the nature to act in hepatocellular carcinoma therapy by targeting the tumor immunosuppressive microenvironment: a review. Molecules. 2022;28(1):195.

Article  PubMed  PubMed Central  Google Scholar 

Gao J, Yin Z, Wu Z, Sheng Z, Ma C, Chen R, Zhang X, Tang K, Fei J, Cao Z. Probing synergistic targets by natural compounds for hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:715762.

Article  PubMed  PubMed Central  Google Scholar 

Mohamed AH, Ezzeldein SME-D, Mosaad AA-W. Effects of natural compounds in treatment and prevention of hepatotoxicity and hepatocellular carcinoma. Hepatoma Res. 2015;1:111–8.

Article  Google Scholar 

Zheng Y, Zhang W, Xu L, Zhou H, Yuan M, Xu H. Recent progress in understanding the action of natural compounds at novel therapeutic drug targets for the treatment of liver cancer. Front Oncol. 2021;11:795548.

Article  CAS  PubMed  Google Scholar 

El-Nakeep S. Molecular and genetic markers in hepatocellular carcinoma: in silico analysis to clinical validation (current limitations and future promises). World J Gastrointest Pathophysiol. 2022;13(1):1–1.

Article  PubMed  PubMed Central  Google Scholar 

Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential biomarkers for liver cancer diagnosis based on multi-omics strategy. Front Oncol. 2022;12:822449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol. 2015;2(4):371–371.

Article  PubMed  PubMed Central  Google Scholar 

Kancherla V, Abdullazade S, Matter MS, Lanzafame M, Quagliata L, Roma G, Hoshida Y, Terracciano LM, Ng CKY, Piscuoglio S. Genomic analysis revealed new oncogenic signatures in TP53-mutant hepatocellular carcinoma. Front Genet. 2018;9:2.

Article  PubMed  PubMed Central  Google Scholar 

Maravelia P, Silva DN, Rovesti G, Chrobok M, Stål P, Lu YC, Pasetto A. Liquid biopsy in hepatocellular carcinoma: opportunities and challenges for immunotherapy. Cancers. 2021;13(17):4334–4334.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50(2):136–42.

Article  CAS  PubMed  Google Scholar 

Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol: WJG. 2015;21(37):10573–10573.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. J Transl Med. 2017;15(1):1–10.

Article  Google Scholar 

Adeniji N, Dhanasekaran R. Current and emerging tools for hepatocellular carcinoma surveillance. Hepatol Commun. 2021;5(12):1972–1972.

Article  PubMed  PubMed Central  Google Scholar 

Marquardt JU, Andersen JB. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepatic Oncology. 2015;2(1):79–79.

Article  PubMed  PubMed Central  Google Scholar 

Dong Y, Wang A. Aberrant DNA methylation in hepatocellular carcinoma tumor suppression (Review). Oncol Lett. 2014;8(3):963–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ratti M, Lampis A, Ghidini M, Salati M, Mirchev MB, Valeri N, Hahne JC. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15(3):261–261.

Article  PubMed  PubMed Central  Google Scholar 

Hsu CC, Lee HC, Wei YH. Mitochondrial DNA alterations and mitochondrial dysfunction in the progression of hepatocellular carcinoma. World J Gastroenterol: WJG. 2013;19(47):8880–8880.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bararia A, Chakraborty P, Roy P, Chattopadhay BK, Das A, Chatterjee A, Sikdar N. Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. World J Gastroenterol. 2023;29(15):2241–2241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-‘t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH, Hochberg F. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2(1):20360.

Article  Google Scholar 

Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation. 2011;123(10):1116–1116.

Article  PubMed